Phase 2 Crohn's Disease and Colitis Trial, Recruiting NCT00692939 Sponsor: Paul Szabolcs Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Phase 2 Crohn's Disease and Colitis Trial, Recruiting

NCT00692939
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You (or your guardian) must be able to understand and agree to take part in the study
  • You must be between 10 and 60 years old (inclusive) at the time of signing the consent form
  • You have Crohn's disease that has come back severely after surgery, even with strong ongoing treatment
  • You have widespread Crohn's disease affecting much of your bowel and have not responded to strong medical treatment, and surgery is not safely possible
  • Your Crohn's disease activity scores remain high, or your disease is at a moderate level but you cannot stop taking daily steroid medication
  • You have serious complications from Crohn's disease (such as abnormal connections between organs, severe skin problems, severe joint pain, or serious bone problems) that have not responded to treatment
  • You had serious side effects from Crohn's medications (such as certain immune-suppressing or biologic drugs) that prevent you from continuing them
  • You have a stoma (a surgically created opening in your abdomen for waste) and are still eligible
  • Surgery is not an option due to risk of your bowel being too short to function, or because you have chosen not to have surgery
  • Your blood platelet count is high enough (above 100,000/mm³)
  • Your white blood cell (neutrophil) count is high enough (above 1,500/mm³, with some exceptions)
  • Your kidney function is within an acceptable range (creatinine at or below 2.0 mg/dL)
  • Your heart function is within an acceptable range (no history of heart artery disease, and heart pumping strength meets minimum levels)
  • Your lung function is within an acceptable range based on breathing tests
  • If you are female and aged 10 or older, or have started your period, you must have a negative pregnancy test (unless you have had surgery that means you cannot become pregnant)
  • All females who could become pregnant, and all sexually active males, must agree to use an approved form of birth control for up to 24 months after the transplant, or for as long as required by any medication that could affect a pregnancy

Who may not be able to join:

  • You have not yet tried standard medications (such as 6-MP, 5-ASA products, and metronidazole) at appropriate doses
  • Your Crohn's disease responded well and stayed in remission without steroids after at least 4 months of biologic therapy (such as anti-TNF, anti-integrin, or anti-IL12/23 treatments)
  • You have a severely swollen, dilated colon (toxic megacolon) or a hole in your intestine (perforation)
  • Your liver function is outside the acceptable range (certain bilirubin levels too high)
  • You are currently pregnant or breastfeeding
  • You have tested positive for certain serious infections, including HIV, HTLV, Hepatitis B, or Hepatitis C
  • You have an active infection confirmed by testing within two weeks before starting the preparation for the transplant
  • You have other health problems, physical findings, or test results that the study doctor believes could put you at extra risk, affect your ability to take part, or affect the study results (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Paul Szabolcs, MD, University of Pittsburgh

Phone: 412-692-5552

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Paul Szabolcs
Registry
ClinicalTrials.gov
Start date
26 June 2012
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of participants with regimen-related toxicities.; Number of participants with life-threatening infections.; Change and duration in the Harvey Bradshaw Index (HBI).; Change and duration in the Crohn's Disease Activity Index (CDAI).; Change and duration in the Pediatric Crohn's Disease Activity Index (PCDAI).

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov